Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Pharma channel feed
Amid buzz around a short seller’s FBI visit, MiMedx stock craters following internal investigation
8 years ago
AstraZeneca hauls kidney disease drug into the clinic after handing Ionis $30M in cash, $300M in milestones
8 years ago
R&D
Did the FDA just leave the door cracked open for PTC’s Duchenne drug after repeated slapdowns?
8 years ago
AbbVie steers past the wreckage, reserves $224M to kick off once-and-done gene therapy with Voyager to fight Alzheimer’s
8 years ago
R&D
White House: Merck and others hit by NotPetya were collateral damage in Russia’s cyberwar on the Ukraine
8 years ago
FDA advisory group rejects Pacira’s pitch for expanded use of pain drug
8 years ago
Bioverativ inks $100M gene therapy deal with Oxford BioMedica
8 years ago
Cell/Gene Tx
After a slapdown on Orkambi price, Vertex is dropping French trial sites while warning patients on access
8 years ago
Woeful Axovant starts axing staff, but departing CEO David Hung gets a $2.6M exit package/bonus
8 years ago
R&D
FDA's Gottlieb outlines new goals in budget plan, looking to spur drug reviews
8 years ago
J&J wins snap approval of apalutamide, the first drug OK'd for nonmetastatic prostate cancer
8 years ago
Senior Merck chemist charged with risking catastrophe after pouring cyanide into Pennsylvania stormwater drain
8 years ago
Switzerland's Ferring Pharma to build $32M discovery, development and manufacturing center at HQ
8 years ago
What does biotech think about ‘right-to-try'? It might surprise you
8 years ago
Bristol-Myers lassos the next big thing in I/O, grabs '214 rights in a record $3.6B deal with Nektar
8 years ago
Novartis, Momenta grab a delayed FDA OK for blockbuster Copaxone knockoff
8 years ago
On a roll, Vertex grabs FDA OK for CF double shot Symdeko — prices at $292,000
8 years ago
Taking on a big challenge, ex-Celgene CEO Bob Hugin readies a run for the Senate
8 years ago
People
What's the trouble with pain? Analysis shows scarce investments, high failure rate for new drugs
8 years ago
R&D
Once rejected, FDA now rolls out a short red carpet for Amicus’ migalastat
8 years ago
What's he thinking about? Vivek Ramaswamy lines up a heavyweight title fight for a late-stage diabetes drug
8 years ago
Market crash slumps biotech as investors yank $1.2B from funds
8 years ago
Seattle Genetics seeds a new immuno-oncology collaboration with the protein explorers at Pieris
8 years ago
R&D
In latest blow to Teva, CGRP migraine med could be delayed while rivals race towards the finish line
8 years ago
First page
Previous page
303
304
305
306
307
308
309
Next page
Last page